Oaktree Specialty Lending (NASDAQ:OCSL) Reports Q2 CY2026 In Line With Expectations

Oaktree Specialty Lending (NASDAQ: OCSL) reported Q2 CY2026 results. Revenue was $69.43 million, down 7.8% year over year and in line with Wall Street expectations. Non-GAAP EPS was $0.34, 4.7% below analysts’ consensus. The stock was reported flat at $12.18 after results.

Original reporting
Published Aug 5, 2026, 12:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 12:50 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Oaktree Specialty Lending (NASDAQ:OCSL) Reports Q2 CY2026 In Line With Expectations — source image
Decision brief

The 30-second read

$OCSLNeutralLow
01

Why it matters

Q2 CY2026 results show a YoY revenue decline and a small non-GAAP EPS miss versus consensus, which typically limits upside catalysts until management provides clearer forward guidance or credit metrics improve.

02

Market read

This is a modest earnings execution story for OCSL, with in-line revenue but slightly weaker EPS, leading to limited immediate stock movement per the article.

03

What to watch

The article flags that some historical revenue comparisons were distorted by outlier investment gains or losses, which could also matter for interpreting the recent decline.

Relevance 4/10Novelty 3/10Timing: post-Q2 results, immediately after reporting

Background

Oaktree Specialty Lending is a business development company managed by Oaktree Capital Management, providing financing to mid-market companies.

Company-level read

Ticker impact

$OCSLNeutralMedium confidence
Context

Oaktree Specialty Lending reported Q2 CY2026 revenue of $69.43M, down 7.8% YoY, with non-GAAP EPS of $0.34 missing consensus by 4.7%.

Expected impact

Near-term reaction likely muted or negative, with traders watching whether the revenue decline and EPS miss reflect worsening fundamentals or timing effects.

Evidence & confidence

The article provides concrete quarterly figures (revenue decline, EPS miss) and notes the stock was flat around $12.18 immediately after reporting, implying limited incremental repricing.

Market effects

BDC earnings quality and credit-risk expectations may remain sensitive to EPS execution even when revenue is steady.

No specific regional spillover mentioned.

No global macro or cross-border catalyst mentioned.

Counterpoint

The revenue print was in line and the stock was flat after results, suggesting the market may already be positioned for a modest EPS miss.

Key entities

  • Oaktree Specialty Lending

    BDC reporting Q2 CY2026 revenue of $69.43M (down 7.8% YoY) and non-GAAP EPS of $0.34 (4.7% below consensus).

  • Oaktree Capital Management

    Manager of OCSL, referenced in the company overview.

Related articles

$OCSLMed

Oaktree Specialty Lending Corp (OCSL): Results of Operations and Financial Condition

Oaktree Specialty Lending Corp (OCSL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d158058dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Oaktree Specialty Lending Corporation Announces Third Fiscal Quarter 2026 Financial Results LOS ANGELES, CA, August 5, 2026 - Oaktree Specialty Lending Corporation (NASDAQ: OCSL) (“Oaktree Specialty Lending” or the “Company

$CPKMedAI 8/10

Chesapeake Utilities (CPK) Q2 2026 Earnings Call Transcript

Chesapeake Utilities (CPK) reported Q2 2026 adjusted net income of $25.4 million, up 5% year over year, and adjusted EPS of $1.05. Management raised 2026 capital guidance to $550 million to $600 million and expects 2028 EPS of $7.75 to $8.00. It also discussed the $1.2 billion Florida Energy Pathway project and reaffirmed efficiency and dividend plans.

$QNSTHighAI 9/10

QuinStreet (QNST) Q4 2026 Earnings Call Transcript

QuinStreet (QNST) reported Q4 FY2026 revenue of $373.9M, up 43% y/y, and full-year revenue of $1.3B, up 18% y/y, driven by Financial Services and Home Services. Adjusted EBITDA rose to $41.4M (11.1% margin). Non-GAAP EPS was $0.50 in Q4. Q1 2027 revenue guidance is $370M-$380M.

$AVPTMedAI 9/10

AvePoint (AVPT) Q2 2026 Earnings Call Transcript

AvePoint (AVPT) reported Q2 2026 revenue of $124.5M, up 22% YoY, with SaaS revenue $98.5M (79% of total). Total ARR was $465.1M (+27%), net new ARR $29.9M, and GAAP operating margin 8.2%. Full-year guidance: ARR $522.1M-$528.1M and revenue $508.5M-$512.5M. The company also spent $50M on share repurchases in Q2.

$NUTXMedAI 8/10

Nutex Health (NUTX) Q2 2026 Earnings Call Transcript

Nutex Health (NUTX) reported Q2 2026 results on an earnings call. Total revenue fell to $210.8M from $244.0M. Net income rose to $65.8M, diluted EPS to $9.38, and adjusted EBITDA to $90.0M. Management cited lower contract services costs from a HaloMD amendment and higher patient visits, plus a hospital expansion pipeline.

$ALRMMedAI 9/10

Alarm.com (ALRM) Q2 2026 Earnings Call Transcript

Alarm.com (ALRM) reported Q2 2026 results. SaaS and license revenue was $188.8 million, up 11.1% YoY and above guidance midpoint. Total revenue rose 9.2% to $277.7 million. Non-GAAP adjusted EBITDA was $57.7 million, up 15.7%, and adjusted EPS was $0.77. Full-year guidance was raised for SaaS, total revenue, and adjusted EBITDA.